Quick Answer
Moderna, Inc. reported Cash And Cash Equivalents At Carrying Value of $2.60 billion for the year ending 2025.
- Moderna, Inc. showed an increase of +34.7% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Moderna, Inc.'s annual report (Form 10-K), filed with the SEC on February 20, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $90.48 million | Q2 2018: $140.62 million | Q3 2018: $167.06 million | Q1 2019: $502.93 million | Q2 2019: $151.62 million | Q3 2019: $173.71 million | Q1 2020: $392.00 million | Q2 2020: $1.76 billion | Q3 2020: $1.51 billion | Q1 2021: $5.44 billion | Q2 2021: $5.60 billion | Q3 2021: $5.55 billion | Q1 2022: $5.05 billion | Q2 2022: $2.87 billion | Q3 2022: $3.03 billion | Q1 2023: $3.44 billion | Q2 2023: $3.80 billion | Q3 2023: $2.93 billion | Q1 2024: $2.05 billion | Q2 2024: $2.48 billion | Q3 2024: $1.64 billion | Q1 2025: $1.62 billion | Q2 2025: $1.28 billion | Q3 2025: $1.13 billion.
- Over the full 11 years of available data (2015 to 2025), Moderna, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 1,531.6%.
- Historical annual values: Fiscal year 2025: $2.60 billion | Fiscal year 2024: $1.93 billion | Fiscal year 2023: $2.91 billion | Fiscal year 2022: $3.21 billion | Fiscal year 2021: $6.85 billion | Fiscal year 2020: $2.62 billion | Fiscal year 2019: $236.00 million | Fiscal year 2018: $658.36 million | Fiscal year 2017: $134.86 million | Fiscal year 2016: $50.08 million | Fiscal year 2015: $159.04 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: